RADNCT06948331
RADA16 for Aquablation Day Case
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
Minor Completed without a posted recruiting period Show 4 more changesShow less
- Primary completion date changed from estimate of Jul 1, 2026 to Sep 17, 2026
- Enrollment target: estimated 25 to confirmed 24
- Study completion date changed from estimate of Aug 1, 2026 to Oct 21, 2026
- Start date changed from estimate of Apr 1, 2026 to May 14, 2026
- Notable Primary completion date: Aug 1, 2025 to Jul 1, 2026
- Start date: May 1, 2025 to Apr 1, 2026
- Study completion date: Sep 1, 2025 to Aug 1, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Patients Discharged the Same Day as Aquablation
Timeframe: Day 1 (Operative Visit)
Secondary (2)
Mean Post-Operation Hematuria Grade
Percentage of Patients who Experience Dysuria during Follow-Up
Arms and interventions
Men Undergoing AquablationExperimental
Following the Aquablation procedure for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), the surgeon will deliver the PuraStat to the prostatic fossa through the cystoscope sheath into the prostate urethra resection bed.
Devices: PuraStat
Sites
1 site in 1 country
- NYU Langone HealthNew York, New York, United States